Guest guest Posted December 22, 2010 Report Posted December 22, 2010 J Viral Hepat. 2010 Dec 8. doi: 10.1111/j.1365-2893.2010.01401.x. [Epub ahead of print] Is chronic hepatitis B being undertreated in the United States? Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM. Hepatitis B Foundation, Doylestown, PA Centers for Disease Control and Prevention, Epidemiology and Surveillance Branch, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA Alaska Native Medical Center, Liver Disease and Hepatitis, Anchorage, AK Children's Hospital and Research Center, Oakland California Pacific Medical Center, Liver Transplant Program, San Francisco, CA Fox Chase Cancer Center, Philadelphia, PA, USA. Abstract Summary.  Chronic infection with the hepatitis B virus (HBV) is a major risk factor for development of end-stage liver disease, including cirrhosis, liver failure and primary liver cancer. There are now seven antiviral agents approved by the United States Food and Drug Administration (FDA) for the management of chronic HBV infection. Despite the fact that there are between 1.4 and 2 million chronic HBV infections in the United States, fewer than 50 000 people per year receive prescriptions for HBV antiviral medications. This report discusses possible explanations for the disparity between the number of people who are chronically infected and the number of people who receive treatment. Explanations for this incongruence include the potentially large number of infected persons who are unscreened and thus remain undiagnosed, and lack of access, including insurance, education and referral to appropriate medical care, particularly for disproportionately infected populations. © 2010 Blackwell Publishing Ltd. PMID: 21143343 [PubMed - as supplied by publisher] Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.